Tirzepatide
Dual GIP/GLP-1 receptor agonist for enhanced weight loss and metabolic health.
Fat loss + mitochondrial + gut repair - tirz core. · 4 Weeks
What Is Tirzepatide?
If you’re looking to buy Tirzepatide Europe, it helps to understand how this peptide works. Approved by the FDA in May 2022, Tirzepatide was the first therapy to combine GIP and GLP-1 receptor activity in a single molecule.
Earlier incretin therapies worked through a single receptor. In clinical trials, Tirzepatide was associated with greater average weight loss than Semaglutide, which will be examined in the section below.
How Does Tirzepatide Differ from Semaglutide?
Both are commonly grouped together as weight loss peptides, but they are not the same compound. Semaglutide works through the GLP-1 receptor. Tirzepatide interacts with both GLP-1 and GIP receptors, giving it a broader incretin profile:
The GLP-1 pathway is linked to appetite regulation, slower gastric emptying (the rate at which food leaves the stomach), and improved insulin sensitivity.
The GIP pathway appears to support nutrient handling and fat metabolism, and may enhance some of the effects associated with GLP-1 receptor activation.
Together, these mechanisms help explain why Tirzepatide has attracted attention in metabolic and weight-management research. The difference in receptor activity has also been reflected in published research.
| Tirzepatide | Semaglutide | |
| Receptors | GIP + GLP-1 | GLP-1 |
| Frequency | Once weekly | Once weekly |
| Weight loss reported in trials | Up to 22.5% at 72 weeks | 14.9% at 68 weeks |
*Based on separate clinical trials. Not to be interpreted as a direct head-to-head comparison.
Clinical Evidence for Tirzepatide
As noted above, SURMOUNT-1 reported some of the strongest weight-loss results seen with an incretin-based therapy. In SURMOUNT-1, participants receiving the 15 mg Tirzepatide dosage lost an average of 22.5% of their starting body weight.
For someone beginning at 105 kg, that equates to roughly 24 kg (53 lbs). At the same dose, 39.7% of participants lost at least 25% of their starting weight.
Researchers also reported improvements in waist circumference and other cardiometabolic measures, including blood pressure, triglycerides, and inflammatory markers.
Who Should Consider Tirzepatide?
Tirzepatide has been evaluated in large studies involving people with obesity, overweight, type 2 diabetes, and related metabolic risk factors. Findings from the SURMOUNT and SURPASS programs have drawn particular attention because of the changes observed in body weight and other cardiometabolic measures.
Many discussions of Tirzepatide benefits focus on its dual receptor activity and the outcomes reported in the SURMOUNT and SURPASS programs.
How to Use Tirzepatide
If you're researching Tirzepatide for sale or comparing different peptide suppliers, it is worth understanding how the compound is typically prepared and administered. Tirzepatide is given once per week by subcutaneous injection and follows a gradual dose-escalation schedule designed to improve tolerability.
Reconstitute Your Vial
Add 2ml of bacteriostatic water to the 10mg vial. This produces a final concentration of 5mg/ml. Direct the water against the inside wall of the vial rather than onto the powder itself, then swirl gently until the solution becomes clear. Avoid shaking.
Titration Protocol
Tirzepatide dosing is usually increased in stages rather than all at once.
- Weeks 1–4: 2.5mg once weekly (50 units, or 0.5ml, when reconstituted with 2ml of bacteriostatic water)
- Weeks 5–8: 5mg once weekly
- Weeks 9–12: 7.5mg once weekly
- Weeks 13–16: 10mg once weekly
- Week 17 onward: Up to 15mg once weekly, depending on tolerability
Dose increases should only be made when the current dose is well tolerated. If gastrointestinal side effects remain significant, it may be appropriate to stay at the same dose for an additional four weeks before increasing.
Injection Technique
Tirzepatide is administered as a subcutaneous injection into the abdomen, upper thigh, or upper arm. Rotate injection sites each week to avoid repeated use of the same area. Many people choose the same day each week to help maintain a consistent dosing schedule.
Storage
Store the reconstituted solution at 2-8°C in a refrigerator. Use within 28 days of reconstitution. Do not freeze. Keep the vial protected from direct light when not in use.
Switched from semaglutide and the dual-action difference is real. Appetite control is stronger and I feel more energy throughout the day.
Lab tested, fast shipping to Netherlands. The 10mg vial lasts well through the titration schedule. Very satisfied.
Effective but the higher doses did cause some GI discomfort initially. Titrating slowly as recommended helped a lot.
Incredible results — 9kg in 10 weeks. Stacking with light resistance training for body composition. Highly recommend.
The dual GIP/GLP-1 mechanism is noticeably more effective than GLP-1 alone. Less hunger between meals and energy levels are great.
Week 6 results are promising. Mild constipation at first but resolved after increasing water intake. Quality product from Morpho.
Ordered twice now. Consistent quality, always arrives within 3 days to Italy. The 10mg vial is great value.
My endocrinologist reviewed the COA and confirmed the purity. Trustworthy supplier. Down 11kg and counting.
Solid peptide. The product page comparison with semaglutide helped me make the right choice for my goals.
Escribir una opinión
Comparte tu experiencia. Tu correo no será publicado.
Predefinido para este producto. Ajusta los valores según tu protocolo.
Why MorphoPeptides?
What sets us apart from other suppliers